Uppsala, Sweden, 24 November 2011
Beactica, the leading Swedish fragment-based drug discovery company spun out from Uppsala University in 2006, was recognised as the fastest growing young biotech in Sweden by management consultants Deloitte at the “Technology Rising Stars” prize giving ceremony in Stockholm this week.
“This result shows we are delivering valued results to our clients and is well deserved by the the world-class team at Beactica,” commented Per Källblad, CEO of Beactica. “We are looking forward to growing our customer base further and also to developing our own drug discovery pipeline using our powerful Sprint platform.”
Deloitte’s annual national Rising Star awards identify new fast-growth technology companies and is part of the Technology Fast 50 program. It ranks new technology companies from all sectors on the basis of growth in revenues over the past three years. Beactica has grown more than 500% in this period making it the 5th ranked Rising Star and highest rank biotech company.
Beactica uses its proprietary technology platform Sprint™ to accelerate and improve drug discovery success for leading pharmaceutical companies, working in important disease areas such as cancer, brain disorders and infectious diseases.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The Company offers expertise and services in the area of surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary Sprint™ platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes. The company has its headquarter in Uppsala, Sweden. For more information, please visit www.beactica.com.